Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting

Phase 3

Sponsor:

NRG Oncology

Code:

NCT05095376

Conditions

Glioblastoma

Gliosarcoma

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Lomustine

Photon Beam Radiation Therapy

Quality-of-Life Assessment

Questionnaire Administration

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information